Download

Download Full Text (569 KB)

Document Type

Poster

Description

GLP-1 therapies show promise in managing type 2 diabetes and obesity in adolescents. This review explores the efficacy, safety, and variations in treatment outcomes. GLP-1 therapies (liraglutide, dulaglutide, exenatide) effectively reduce HbA1c levels. Weight reduction is a positive outcome crucial for type 2 diabetes and obesity management. Safety concerns and gastrointestinal effects emphasize the need for monitoring during GLP-1 therapy. Insights from studies on Lixisenatide offer valuable information for healthcare providers. There is consensus on general effectiveness, but debates on specific outcomes and long-term effects persist. Case-based investigations suggest potential variations in treatment responses, requiring further exploration. Bridging the gap between research and application. Empowering clinicians to make informed decisions, considering individual patient needs for enhanced quality of care.

Department

Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

Date of Work

2024

First Advisor

Metzger, Jay

Second Advisor

Kauffman, Russell

Publication Date

Spring 2024

Disciplines

Medicine and Health Sciences

The Efficacy of GLP-1 Agonists in Pediatrics with Type 2 Diabetes and Obesity

Share

COinS